ELVN insider trading
HealthcareEnliven Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Company website: www.enliventherapeutics.com
ELVN insider activity at a glance
FilingIQ tracks 449 insider transactions for ELVN in filings since Feb 27, 2023. The most recent transaction is dated Oct 1, 2026.
Across the full history, 1 open-market purchases
and 316 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ELVN insider trades is 61.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ELVN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading ELVN
Frequently asked
- How many insider trades does FilingIQ track for ELVN?
- FilingIQ tracks 449 Form 4 insider transactions for ELVN (Enliven Therapeutics, Inc.), covering filings from Feb 27, 2023 onwards. 32 of those are dated within the last 90 days.
- Are ELVN insiders net buyers or net sellers?
- Across the full Form 4 history for ELVN, 1 transactions (0%) were open-market purchases and 316 (70%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ELVN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ELVN in?
- Enliven Therapeutics, Inc. (ELVN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.59B.
Methodology & sources
Every ELVN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.